Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Cyclacel Pharmaceuticals reports disappointing data

The Data and Safety Monitoring Board determined that Cyclacel Pharmaceuticals Inc.'s (Nasdaq: CYCC) ongoing Phase 3 study of sapacitabine was not likely to demonstrate statistically significant improvement in survival. The stock price plummeted $2.15 to close at $0.68.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.